HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a cl

Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Coliti

Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's aft

Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.69) per share which beat the anal

Reported topline healthy volunteer  results for next-generation STAT3 inhibitor TTI-109, confirming

Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stag

HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NA

BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers th

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative c

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular

Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerabilit

Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for T

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's

Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's

Raymond James analyst Ryan Deschner upgrades Tvardi Therapeutics (NASDAQ:TVRD) from Market Perfor

Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prod

Tvardi Therapeutics (TVRD) stock jumps 50% after reporting positive Phase 1 data for its next-gen ST

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tues

BTIG analyst Julian Harrison reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintain

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions i

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions i

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&

Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&

Top Wall Street analysts changed their outlook on top names. See upgrades, downgrades & initiati

HC Wainwright & Co. analyst Sara Nik initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD)

HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a cli

Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.73) per share which beat the anal

Topline results from healthy volunteer study and clinical development strategy  for next-generation

https://www.sec.gov/Archives/edgar/data/1346830/000110465926054113/tm2613101-1_s3.htm

Tvardi Therapeutics, Inc. (NASDAQ: TVRD - Get Free Report) has received an average recommendation of

Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to U

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a c

Barclays analyst Etzer Darout maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Equal-Weight and

Piper Sandler analyst Yasmeen Rahimi maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Neutral a

Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.78) per share which missed the an

Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 20

Shares of Tvardi Therapeutics, Inc. (NASDAQ: TVRD - Get Free Report) have been given a consensus rat

Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium Presentati

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suf

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suf

NEW YORK--(BUSINESS WIRE)---- $TVRD #Faruqi--Faruqi & Faruqi, LLP, a leading national securities law

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suf

Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.59) per share which beat the anal

Raymond James analyst Ryan Deschner downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Outperform